HRP20100674T1 - Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka - Google Patents
Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka Download PDFInfo
- Publication number
- HRP20100674T1 HRP20100674T1 HR20100674T HRP20100674T HRP20100674T1 HR P20100674 T1 HRP20100674 T1 HR P20100674T1 HR 20100674 T HR20100674 T HR 20100674T HR P20100674 T HRP20100674 T HR P20100674T HR P20100674 T1 HRP20100674 T1 HR P20100674T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- preparation according
- proportion
- active agent
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 3
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 201000011510 cancer Diseases 0.000 title claims 2
- GWEHVDNNLFDJLR-UHFFFAOYSA-N 1,3-diphenylurea Chemical class C=1C=CC=CC=1NC(=O)NC1=CC=CC=C1 GWEHVDNNLFDJLR-UHFFFAOYSA-N 0.000 title 1
- 239000013543 active substance Substances 0.000 claims abstract 10
- 239000000203 mixture Substances 0.000 claims abstract 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000007908 dry granulation Methods 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 229940127084 other anti-cancer agent Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- JODIEZIJHKKWKN-UHFFFAOYSA-N 3-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide Chemical compound CNC(=O)C1=NC=CC=C1OC(C=C1)=CC=C1NC(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 JODIEZIJHKKWKN-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65882705P | 2005-03-07 | 2005-03-07 | |
| PCT/EP2006/001574 WO2006094626A1 (fr) | 2005-03-07 | 2006-02-22 | Composition pharmaceutique comprenant une diphénylurée substituée par un oméga-carboxyaryle pour le traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100674T1 true HRP20100674T1 (hr) | 2011-01-31 |
Family
ID=36507604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100674T HRP20100674T1 (hr) | 2005-03-07 | 2010-12-06 | Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US9737488B2 (fr) |
| EP (1) | EP1868579B1 (fr) |
| JP (1) | JP5304241B2 (fr) |
| KR (1) | KR101335932B1 (fr) |
| CN (2) | CN104688697A (fr) |
| AR (1) | AR054234A1 (fr) |
| AT (1) | ATE482693T1 (fr) |
| AU (1) | AU2006222365B2 (fr) |
| BR (1) | BRPI0608840B8 (fr) |
| CA (1) | CA2601955C (fr) |
| CR (1) | CR9348A (fr) |
| CU (1) | CU23821A3 (fr) |
| CY (1) | CY1111065T1 (fr) |
| DE (1) | DE602006017188D1 (fr) |
| DK (1) | DK1868579T3 (fr) |
| DO (1) | DOP2006000057A (fr) |
| ES (1) | ES2351612T3 (fr) |
| GT (1) | GT200600096A (fr) |
| HK (2) | HK1118019A1 (fr) |
| HN (1) | HN2006009702A (fr) |
| HR (1) | HRP20100674T1 (fr) |
| IL (1) | IL185517A (fr) |
| MA (1) | MA29378B1 (fr) |
| MX (1) | MX2007010856A (fr) |
| MY (1) | MY162319A (fr) |
| NO (1) | NO343834B1 (fr) |
| NZ (1) | NZ561178A (fr) |
| PE (1) | PE20061345A1 (fr) |
| PL (1) | PL1868579T3 (fr) |
| PT (1) | PT1868579E (fr) |
| SG (1) | SG160364A1 (fr) |
| SI (1) | SI1868579T1 (fr) |
| TN (1) | TNSN07341A1 (fr) |
| TW (1) | TWI324928B (fr) |
| UA (1) | UA93673C2 (fr) |
| UY (1) | UY29410A1 (fr) |
| WO (1) | WO2006094626A1 (fr) |
| ZA (1) | ZA200707638B (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| IL144144A0 (en) | 1999-01-13 | 2002-05-23 | Bayer Ag | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| CA2475703C (fr) | 2002-02-11 | 2016-12-20 | Bayer Pharmaceuticals Corporation | Urees aryliques a activite inhibitrice d'angiogenese |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| US20070020704A1 (en) | 2003-05-20 | 2007-01-25 | Scott Wilhelm | Diaryl ureas with kinase inhibiting activity |
| NZ580384A (en) | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| JP5215666B2 (ja) * | 2004-09-29 | 2013-06-19 | バイエル・ファルマ・アクチェンゲゼルシャフト | Ｂａｙ４３−９００６トシレートの熱力学的に安定な形態 |
| CA2601955C (fr) | 2005-03-07 | 2012-07-10 | Bayer Healthcare Ag | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer |
| EP2289515A3 (fr) * | 2005-10-31 | 2012-04-11 | Bayer HealthCare LLC | Combinaison contenant une diaryl urée et un interferon |
| JP2009543797A (ja) * | 2006-07-10 | 2009-12-10 | エラン ファーマ インターナショナル，リミティド | ナノ粒子ソラフェニブ製剤 |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| CA2675980C (fr) | 2007-01-19 | 2016-06-21 | Bayer Healthcare Llc | Utilisation de dast dans le traitement des cancers a resistance acquise a des inhibiteurs de kit |
| WO2009106825A1 (fr) * | 2008-02-27 | 2009-09-03 | Cipla Limited | Polymorphes de sorafénib et leurs sels |
| EP3692983B1 (fr) | 2008-05-15 | 2021-08-11 | Celgene Corporation | Formulations orales d'analogues de cytidine et leurs procédés d'utilisation |
| WO2010142678A2 (fr) * | 2009-06-12 | 2010-12-16 | Ratiopharm Gmbh | Polymorphes de 4-[4-[[4-chloro-3-(trifluorométhyl)phényl]carbamoylamino]phénoxy]-n-méthyl-pyridine-2-carboxamide |
| EP2528899B1 (fr) * | 2010-01-29 | 2014-10-15 | Ranbaxy Laboratories Limited | Solvate de diméthylsulfoxyde du sorafenib |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| EP2621486A1 (fr) | 2010-10-01 | 2013-08-07 | Bayer Intellectual Property GmbH | Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué |
| EP2559431A1 (fr) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Composition pharmaceutique comportant du 4-[4-[[4-Chloro-3-(trifluoromethyl)phényl]carbamoylamino]phénoxy]-N-méthyl-pyridine-2-carboxamide |
| WO2013110644A1 (fr) | 2012-01-23 | 2013-08-01 | Sandoz Ag | Composition pharmaceutique contenant du tosylate de sorafénib cristallin |
| SG11201408067YA (en) | 2012-06-04 | 2015-01-29 | Pharmacyclics Inc | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| AU2015300798A1 (en) | 2014-08-07 | 2017-02-02 | Pharmacyclics Llc | Novel formulations of a Bruton's tyrosine kinase inhibitor |
| FI3265084T3 (fi) | 2015-03-03 | 2024-02-21 | Pharmacyclics Llc | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita |
| JP6877196B2 (ja) * | 2016-03-14 | 2021-05-26 | 参天製薬株式会社 | メグルミン又はその塩からなる防腐剤 |
| CN106344530B (zh) * | 2016-09-30 | 2019-03-19 | 京津冀联创药物研究（北京）有限公司 | 一种索拉非尼组合物及其制备方法 |
| CA3064829C (fr) | 2017-05-26 | 2023-08-22 | Bruin Biosciences, Inc. | Agents pour chimio-embolisation |
| US11179322B2 (en) | 2018-07-10 | 2021-11-23 | Novocure Gmbh | Methods and compositions for treating tumors with TTFields and sorafenib |
| WO2018211336A2 (fr) * | 2018-09-07 | 2018-11-22 | Alvogen Malta Operations (Row) Ltd | Forme galénique solide contenant du tosylate de sorafénib |
| AU2019371454A1 (en) | 2018-11-01 | 2021-05-27 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3125359A (en) * | 1964-03-17 | Push-pull breakaway coupling | ||
| NL282262A (fr) * | 1961-11-08 | |||
| AU594098B2 (en) | 1985-12-11 | 1990-03-01 | Ishihara Sangyo Kaisha Ltd. | N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation |
| DK607188A (da) | 1987-11-02 | 1989-06-22 | Merck & Co Inc | Tablet indeholdende en phthalazineddikesyreforbindelse |
| US5547966A (en) | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
| US6106865A (en) | 1995-01-09 | 2000-08-22 | Edward Mendell Co., Inc. | Pharmaceutical excipient having improved compressibility |
| GB9501127D0 (en) | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
| US5773459A (en) | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
| EP0841910A4 (fr) | 1995-07-25 | 2006-09-13 | Smithkline Beecham Corp | INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE |
| HUP0004421A3 (en) | 1996-04-23 | 2002-10-28 | Vertex Pharmaceuticals Inc Cam | Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme |
| AU7585598A (en) | 1997-05-23 | 1998-12-11 | Bayer Corporation | Raf kinase inhibitors |
| ES2151467T3 (es) | 1997-05-23 | 2005-03-01 | Bayer Corporation | Arilureas para el tratamiento de enfermedades inflamatorias o inmunomoduladoras. |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| DE1049664T1 (de) | 1997-12-22 | 2001-05-03 | Bayer Ag | Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen |
| CA2315715C (fr) | 1997-12-22 | 2010-06-22 | Bayer Corporation | Inhibition de la kinase p38 par des diphenyl-urees symetriques et dissymetriques |
| WO1999032111A1 (fr) | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition de l'activite de p38 kinase au moyen d'urees heterocycliques substituees |
| IL136768A0 (en) | 1997-12-22 | 2001-06-14 | Bayer Ag | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| CA2315717C (fr) | 1997-12-22 | 2011-02-01 | Bayer Corporation | Inhibition de raf kinase au moyen d'urees heterocycliques substituees |
| US20080300281A1 (en) | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
| TR200002617T2 (tr) | 1997-12-22 | 2000-11-21 | Bayer Corporation | Aril ve heteroaril sübstitüentli heterosiklik üreler kullanılarak RAF kinazın inhibe edilmesi |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| US20010014352A1 (en) | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
| US20030087849A1 (en) | 2001-07-03 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of HKR1 expression |
| US6117451A (en) | 1998-08-25 | 2000-09-12 | Pharmalogix, Inc. | Direct compression metformin hydrochloride tablets |
| US20080269265A1 (en) | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| IL144144A0 (en) | 1999-01-13 | 2002-05-23 | Bayer Ag | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ME00275B (fr) | 1999-01-13 | 2011-02-10 | Bayer Corp | DIPHENYLUREES A SUBSTITUANTS ω-CARBOXYARYLES, INHIBITRICES DE KINASE RAF |
| US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
| WO2000042012A1 (fr) | 1999-01-13 | 2000-07-20 | Bayer Corporation | DIPHENYLUREES A SUBSTITUANTS φ-CARBOXYARYLES, INHIBITRICES DE KINASE RAF |
| PL204856B1 (pl) | 1999-01-22 | 2010-02-26 | Kirin Pharma Kk | Pochodne chinoliny lub chinazoliny, jej zastosowanie i kompozycja farmaceutyczna |
| ES2265439T3 (es) * | 2000-08-18 | 2007-02-16 | Pharmacia Corporation | Formulacion oral de valdecoxib que se desintegra rapidamente. |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| PE20020958A1 (es) | 2001-03-23 | 2002-11-14 | Bayer Corp | Inhibidores de la rho-quinasa |
| US20030207914A1 (en) | 2001-04-20 | 2003-11-06 | Bayer Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| CA2443950C (fr) | 2001-04-20 | 2011-10-18 | Bayer Corporation | Inhibition de la kinase raf a l'aide d'urees de quinolyl, d'isoquinolyl ou de pyridyl |
| MEP36208A (en) | 2001-12-03 | 2011-02-10 | Bayer Corp | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| JP2005526008A (ja) * | 2001-12-04 | 2005-09-02 | オニックス ファーマシューティカルズ，インコーポレイティド | 癌を処置するためのｒａｆ−ｍｅｋ−ｅｒｋ経路インヒビター |
| US20030207872A1 (en) * | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US20080108672A1 (en) | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
| PT1580188E (pt) | 2002-02-11 | 2012-01-25 | Bayer Healthcare Llc | Aril-ureias como inibidores de cinases |
| US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
| WO2003068229A1 (fr) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | N-oxydes de pyridine, de quinoline, et d'isoquinoline en tant qu'inhibiteurs de kinase |
| AU2003210969A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
| CA2475703C (fr) | 2002-02-11 | 2016-12-20 | Bayer Pharmaceuticals Corporation | Urees aryliques a activite inhibitrice d'angiogenese |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| WO2003101444A1 (fr) | 2002-05-29 | 2003-12-11 | Millennium Pharmaceuticals, Inc. | Composes et derives de diaryluree utilises comme inhibiteurs de chk-1 dans le traitement du cancer |
| ATE489379T1 (de) | 2003-02-28 | 2010-12-15 | Bayer Healthcare Llc | 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen |
| EP1608639A2 (fr) | 2003-02-28 | 2005-12-28 | Bayer Pharmaceuticals Corporation | Nouveaux derives bicycliques d'uree utiles dans le traitement du cancer et d'autres troubles |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| WO2004078128A2 (fr) | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Derives de pyridine substitues utilises pour traiter des cancers et d'autres troubles |
| US6896863B2 (en) | 2003-04-01 | 2005-05-24 | E. I. Du Pont De Nemours And Company | Sodium cyanide process |
| US20070020704A1 (en) | 2003-05-20 | 2007-01-25 | Scott Wilhelm | Diaryl ureas with kinase inhibiting activity |
| US20060234931A1 (en) * | 2003-07-17 | 2006-10-19 | Biggs William H Iii | Treatment of diseases with kinase inhibitors |
| NZ580384A (en) | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| KR20060097000A (ko) | 2003-09-23 | 2006-09-13 | 노파르티스 아게 | 화학요법제와 ｖｅｇｆ 수용체 저해제의 배합물 |
| US7552093B2 (en) * | 2003-12-04 | 2009-06-23 | Black Duck Software, Inc. | Resolving license dependencies for aggregations of legally-protectable content |
| WO2005059179A1 (fr) | 2003-12-12 | 2005-06-30 | Bayer Pharmaceutical Corporation | Procede de prediction et de pronostic du cancer, et surveillance de traitement anticancereux |
| EP1751139B1 (fr) | 2004-04-30 | 2011-07-27 | Bayer HealthCare LLC | Derives de pyrazolyl uree substitues utiles dans le traitement du cancer |
| MXPA06015267A (es) | 2004-06-22 | 2007-03-15 | Pfizer Prod Inc | Antagonistas diazabiciclicos del receptor histamina-3. |
| CA2578442A1 (fr) | 2004-08-27 | 2006-03-09 | Bayer Pharmaceuticals Corporation | Compositions pharmaceutiques comprenant un amide methylique de l'acide 4{4-[3-(4-chloro-3-(trifluoromethyl)phenyl)ureido]phenoxy}pyridine-2-carboxylique pour le traitement du cancer |
| MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| BRPI0515944B1 (pt) | 2004-09-29 | 2021-11-09 | Bayer Healthcare Llc | Processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fe-nil]amino}carbonil) amino]fenóxi}nmetilpiridina-2-carboxamida |
| JP5215666B2 (ja) | 2004-09-29 | 2013-06-19 | バイエル・ファルマ・アクチェンゲゼルシャフト | Ｂａｙ４３−９００６トシレートの熱力学的に安定な形態 |
| CA2601955C (fr) | 2005-03-07 | 2012-07-10 | Bayer Healthcare Ag | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer |
| KR20080012902A (ko) | 2005-05-27 | 2008-02-12 | 바이엘 헬스케어 아게 | 질병을 치료하기 위한 디아릴 우레아를 포함하는 병용요법 |
| JP2008542214A (ja) | 2005-05-27 | 2008-11-27 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 疾患を処置するためのジアリールウレア化合物およびｐｉ３、ａｋｔキナーゼまたはｍｔｏｒ阻害剤（ラパマイシン）を含む組合せ治療 |
| EP1937837A2 (fr) | 2005-07-29 | 2008-07-02 | Siemens Healthcare Diagnostics Inc. | Methodes et trousses pour la prediction du succes therapeutique, de la survie sans recidive et globale dans des therapies du cancer |
| US20090221010A1 (en) | 2005-10-21 | 2009-09-03 | Elting James J | Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy |
| EP2289515A3 (fr) | 2005-10-31 | 2012-04-11 | Bayer HealthCare LLC | Combinaison contenant une diaryl urée et un interferon |
| WO2007053573A2 (fr) | 2005-10-31 | 2007-05-10 | Bayer Pharmaceuticals Corporation | Traitement du cancer au moyen de sorafenib |
| US8329408B2 (en) | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
| WO2007056012A2 (fr) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Llc | Methodes pour la prevision et le pronostic du cancer, et pour la surveillance de therapie anticancereuse |
| WO2007056011A2 (fr) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Llc | Methodes pour la prevision et le pronostic du cancer, et pour la surveillance de therapie anticancereuse |
| PT1948176E (pt) | 2005-11-10 | 2011-03-07 | Bayer Schering Pharma Ag | Diaril ureias para tratar a hipertensão pulmonar |
| CN101454668A (zh) | 2005-11-14 | 2009-06-10 | 拜耳医药保健有限责任公司 | 癌症预测与预后以及监测癌症治疗的方法 |
| WO2007059155A1 (fr) | 2005-11-14 | 2007-05-24 | Bayer Pharmaceuticals Corporation | Traitement de cancers a resistance a des agents chimiotherapeutiques |
| EP1957069A2 (fr) | 2005-11-14 | 2008-08-20 | Bayer Healthcare, LLC | Traitement de cancers a resistance acquise a des inhibiteurs de kit |
| MX2008006979A (es) | 2005-12-01 | 2009-01-14 | Bayer Healthcare Llc | Compuestos de urea utiles en el tratamiento contra el cancer. |
| US20090227637A1 (en) | 2005-12-15 | 2009-09-10 | Olaf Weber | Diaryl ureas for treating virus infections |
| EP2111401B1 (fr) | 2006-12-20 | 2011-02-16 | Bayer HealthCare, LLC | 4- {4-[({3- tert- butyl-1- [3- (hydroxymethyl) phenyl]- 1h- pyrazol- 5- yl } carbamoyl) -amino]- 3- fluorophenoxy} - n- methylpyridine- 2- carboxamide ainsi que des promédicaments et des sels de ceux-ci utilisés pour traiter un cancer |
| CA2675980C (fr) | 2007-01-19 | 2016-06-21 | Bayer Healthcare Llc | Utilisation de dast dans le traitement des cancers a resistance acquise a des inhibiteurs de kit |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| WO2013000909A1 (fr) | 2011-06-28 | 2013-01-03 | Bayer Intellectual Property Gmbh | Composition pharmaceutique topique ophtalmologique contenant du sorafénib |
| EP2559431A1 (fr) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Composition pharmaceutique comportant du 4-[4-[[4-Chloro-3-(trifluoromethyl)phényl]carbamoylamino]phénoxy]-N-méthyl-pyridine-2-carboxamide |
-
2006
- 2006-02-22 CA CA2601955A patent/CA2601955C/fr active Active
- 2006-02-22 DE DE602006017188T patent/DE602006017188D1/de active Active
- 2006-02-22 JP JP2008500066A patent/JP5304241B2/ja active Active
- 2006-02-22 WO PCT/EP2006/001574 patent/WO2006094626A1/fr active Application Filing
- 2006-02-22 KR KR1020077020370A patent/KR101335932B1/ko active IP Right Review Request
- 2006-02-22 PT PT06707141T patent/PT1868579E/pt unknown
- 2006-02-22 SI SI200630863T patent/SI1868579T1/sl unknown
- 2006-02-22 PL PL06707141T patent/PL1868579T3/pl unknown
- 2006-02-22 UA UAA200711110A patent/UA93673C2/ru unknown
- 2006-02-22 EP EP06707141A patent/EP1868579B1/fr not_active Revoked
- 2006-02-22 NZ NZ561178A patent/NZ561178A/en unknown
- 2006-02-22 BR BRPI0608840A patent/BRPI0608840B8/pt active IP Right Grant
- 2006-02-22 SG SG201001549-3A patent/SG160364A1/en unknown
- 2006-02-22 AU AU2006222365A patent/AU2006222365B2/en active Active
- 2006-02-22 MX MX2007010856A patent/MX2007010856A/es active IP Right Grant
- 2006-02-22 CN CN201510055041.5A patent/CN104688697A/zh active Pending
- 2006-02-22 AT AT06707141T patent/ATE482693T1/de active
- 2006-02-22 DK DK06707141.5T patent/DK1868579T3/da active
- 2006-02-22 US US11/885,930 patent/US9737488B2/en active Active
- 2006-02-22 CN CN200680007187.1A patent/CN101132779B/zh not_active Ceased
- 2006-02-22 ES ES06707141T patent/ES2351612T3/es active Active
- 2006-02-27 GT GT200600096A patent/GT200600096A/es unknown
- 2006-03-03 DO DO2006000057A patent/DOP2006000057A/es unknown
- 2006-03-03 MY MYPI20060919A patent/MY162319A/en unknown
- 2006-03-03 AR AR20060100820A patent/AR054234A1/es not_active Application Discontinuation
- 2006-03-06 TW TW095107345A patent/TWI324928B/zh active
- 2006-03-06 UY UY29410A patent/UY29410A1/es not_active Application Discontinuation
- 2006-03-06 PE PE2006000250A patent/PE20061345A1/es active IP Right Grant
- 2006-03-07 HN HN2006009702A patent/HN2006009702A/es unknown
-
2007
- 2007-08-27 IL IL185517A patent/IL185517A/en active IP Right Grant
- 2007-08-28 CR CR9348A patent/CR9348A/es unknown
- 2007-08-30 CU CU20070203A patent/CU23821A3/es active IP Right Grant
- 2007-09-05 ZA ZA200707638A patent/ZA200707638B/xx unknown
- 2007-09-06 TN TNP2007000341A patent/TNSN07341A1/en unknown
- 2007-10-02 MA MA30267A patent/MA29378B1/fr unknown
- 2007-10-05 NO NO20075042A patent/NO343834B1/no unknown
-
2008
- 2008-08-19 HK HK08109248.3A patent/HK1118019A1/zh unknown
-
2010
- 2010-12-06 HR HR20100674T patent/HRP20100674T1/hr unknown
- 2010-12-10 CY CY20101101138T patent/CY1111065T1/el unknown
-
2015
- 2015-10-22 HK HK15110355.1A patent/HK1209620A1/xx unknown
-
2017
- 2017-08-22 US US15/683,210 patent/US20180036249A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100674T1 (hr) | Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka | |
| JP2021038242A (ja) | ルカパリブの高投与力価錠剤 | |
| US10064826B2 (en) | Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process | |
| HRP20192064T1 (hr) | Formulacije apiksabana | |
| HRP20161262T1 (hr) | Tablete ulipristal acetata | |
| ITMI20001450A1 (it) | Nuova composizione farmaceutica | |
| ZA200508361B (en) | Orally disintegrating tablets | |
| JP2016536285A (ja) | アムロジピン及びバルサルタンを含む安定な医薬組成物 | |
| JPS6241646B2 (fr) | ||
| US20140335176A1 (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing | |
| JP6009967B2 (ja) | 固形製剤 | |
| JP2017122056A (ja) | 医薬含有造粒物の製造方法 | |
| JP2012529431A (ja) | トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤 | |
| JP6308938B2 (ja) | 粒状物を製造する方法 | |
| CN102349915A (zh) | 一种氨酚咖敏维c制剂及其制备方法 | |
| JP2011246428A (ja) | 口腔内崩壊型医薬品及びその製造方法 | |
| JP2007332074A (ja) | 口腔内速崩壊錠およびその製造方法 | |
| JP2017520619A (ja) | セリチニブ製剤 | |
| JP2004522780A5 (fr) | ||
| HRP20191669T1 (hr) | Farmaceutski sastav koji sadrži polimer koji veže fosfate | |
| CA3122196A1 (fr) | Procede de fabrication de comprimes a ingestion facile contenant un extrait sec de feuilles de ginkgo biloba | |
| CZ2007169A3 (cs) | Farmaceutická kompozice s obsahem úcinné látky atorvastatinu | |
| JP2005502729A (ja) | 植物抽出物から錠剤を製造するための方法 | |
| CA3048968A1 (fr) | Composition pharmaceutique orale de lurasidone et sa preparation | |
| ES2954286T3 (es) | Composiciones de piridostigmina de liberación sostenida |